J&J Medical Connect
TREMFYA®

(guselkumab)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

Switching Patients with Plaque Psoriasis from Risankizumab or Tildrakizumab to TREMFYA

Last Updated: 11/18/2026

SUMMARY

  • The company cannot recommend any practices, procedures, or usage of TREMFYA that deviate from the approved labelling.
  • Summarized in this response are relevant data from retrospective studies regarding switching patients with plaque psoriasis (PsO) from risankizumab or tildrakizumab to TREMFYA.1,2

CLINICAL DATA

  • Retrospective Studies

Caldarola et al (2025)1 conducted an observational, retrospective, multicenter study in Italy to evaluate the effectiveness and switching patterns between interleukin-23 (IL-23) inhibitors in patients with plaque PsO in a real-world setting.

Study Design/Methods

  • The study enrolled adult patients with plaque PsO who discontinued an anti-IL-23 therapy and started another drug targeting IL-23 within the following 120 days (from the date of scheduled but unadministered dose).
  • Patients were included if their initial IL-23 inhibitor treatments were discontinued due to adverse events (AEs) or lack of efficacy, when treatment goals were not achieved based on clinical considerations and local guidelines.
  • Exclusion criteria included patients who received other systemic therapies between the 2 IL-23 inhibitors, patients with combination PsO therapies, and those who did not receive standard doses of IL-23 inhibitors.
  • Primary inefficacy was defined as the failure to achieve treatment goals by week 16 and secondary inefficacy referred to the loss of clinical response after an initial period of therapeutic success.

Results

  • A total of 116 patients were included and 4 patients underwent a double switch between IL-23 agents (total of 120 switches).
  • The primary reason for treatment withdrawal was lack of efficacy (93.3%), comprising secondary inefficacy in 82.5% of patients and primary inefficacy in 10.8%.
  • The average time between the scheduled but unadministered dose of the first biologic and the start of the second was 8.6 ± 24.4 days.
  • A total of 28 (23.3%) patients had TREMFYA as their last IL-23 inhibitor.
    • A total of 18 and 10 patients switched from tildrakizumab and risankizumab, respectively.
    • The mean (standard deviation) treatment duration was 18.1 (±10.1) months.
    • Three (10.7%) patients withdrew from treatment, due to secondary ineffectiveness.
  • Based on univariate analysis of patients who received TREMFYA as their last IL-23 inhibitor:
    • At week 16, 4 (3.5%) patients achieved ≥90% improvement from baseline in Psoriasis Area and Severity Index score (PASI 90), while 23 (19.8%) were PASI 90 non-responders (P=0.12).
    • At week 36, 9 (8.3%) patients were PASI 90 responders, while 15 (13.8%) were PASI 90 non-responders (P=0.26).
    • At week 52, 12 (13.5%) patients were PASI 90 responders, while 8 (9.0%) were PASI 90 non-responders (P=1.00).
  • Hren et al (2024)2 performed a retrospective review to evaluate IL-23 inhibitor intraclass switching in patients with PsO who experienced loss of efficacy to any IL-23 inhibitor.

Study Design/Methods

  • This retrospective chart review included 43 patients with moderate to severe plaque PsO who underwent any of 6 potential iterations of IL-23 intraclass switch between November 2017 and November 2023.
  • Only patients with an initiation of a second IL-23 inhibitor within 90 days of discontinuing the primary IL-23 inhibitor, and without any concurrent or interim systemic therapy, were included.
  • Primary non-response was defined as an insufficient response that warranted a switch within 120 days of initial IL-23 start. Secondary loss of efficacy was defined as achieving <1% body surface area (BSA) affected by PsO at any point during treatment but subsequently presenting with worsening clinical disease.
  • A patient was considered to have “improved” if they reached a BSA <1% after IL-23 inhibitor intraclass switch.

Results

  • During the study period, a total of 43 patients were included in the analysis.
  • Of these, 32.6% (n=14) switched because of primary non-response and 67.4% (n=29) because of secondary loss of efficacy.
  • The most common switch patterns were TREMFYA-to-risankizumab (55.8%; n=24) and tildrakizumab-to-risankizumab (27.9%; n=12). All patients were biologic-experienced and had previously failed a mean of 2.3 ± 1.3 biologic therapies and 2.7 ± 1.7 systemic treatments.
  • Patients experienced loss of efficacy with their primary IL-23 inhibitor after a mean of 453.9 ± 356.7 days. Following an IL-23 intraclass switch, 81.4% (35/43) achieved BSA <1% after a mean of 248.8 ± 126.5 days.
  • Three (7.0%) patients switched from risankizumab to TREMFYA, with 2 of them reporting clinical improvement (achievement of BSA <1%) after switch.
  • Two (4.7%) patients switched from tildrakizumab to TREMFYA, with both reporting
  • clinical improvement after switch.
  • No adverse events were reported.

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, DERWENT® (and other resources, including internal/external databases) was conducted on 12 October 2026.

 

References

1 Caldarola G, Luca ED, Balato A, et al. Intraclass switching of IL-23 inhibitors in psoriasis: Effectiveness, patterns, and predictors of response - A retrospective multicenter study in Italy. Clin Exp Dermatol. 2025;:llaf476.  
2 Hren MG, Miriyala S, Khattri S. The utility of interleukin-23 intraclass switching in the treatment of plaque psoriasis: a retrospective review of 43 cases. Clin Exp Dermatol. 2024;50(1):137-140.  

Would you like to clear and leave your conversation? Message history will be lost.